Roadmap to Formulation Development of Monoclonal Antibodies and Related Proteins: From Pre-Clinical to Commercialization

A symposium on formulation development of monoclonal antibodies and related proteins will explore the integrated pathway from preclinical phases to full commercialization. Sessions will include the formulation development roadmap, high-throughput screening strategies, first-inhuman (FIH) formulation development, Phase 3 formulation optimization, and commercial drug product design. Experts will discuss how a deep understanding of the end-to-end development process accelerates speed to clinic, supports risk mitigation, and ensures successful technology transfer. Emphasis will be placed on balancing rapid FIH readiness with long-term stability,
manufacturability, and patient usability to design robust, commercially viable formulations for therapeutic proteins.

Visit here for more information and to register for the event.

Regular attendees: $300; Self-Paying or Academic: $45

In-Person Workshop; Webcast for Other Chapters